Provide feedbackProvide feedback


GSK, Five Prime establish respiratory disease alliance worth as much as $223.5 million

Tuesday, April 17 2012 | Comments
Evidence Grade 0 What's This?

GlaxoSmithKline Plc (GSK) and Five Prime Therapeutics Inc. entered into a second strategic drug discovery alliance with each other. In signing the agreement, GSK gained exclusive access to Five Prime's drug discovery platforms in as many as six programs to identify first-in-class agents and new mechanisms relevant to refractory asthma and chronic obstructive pulmonary disease. Five Prime will apply its technology platforms to identify and validate potential drug targets and drug...

GlaxoSmithKline Plc (GSK) and Five Prime Therapeutics Inc. entered into a second strategic drug discovery alliance with each other.

In signing the agreement, GSK gained exclusive access to Five Prime's drug discovery platforms in as many as six programs to identify first-in-class agents and new mechanisms relevant to refractory asthma and chronic obstructive pulmonary disease. Five Prime will apply its technology platforms to identify and validate potential drug targets and drug candidates. GSK has the option to exclusively license selected targets Five Prime discovers through the collaboration.

For most of the licensed targets, GSK will be solely responsible for additional preclinical studies, clinical development, manufacturing activities and worldwide product commercialization; however, for a limited number of the targets, Five Prime will have the opportunity to advance biologic products through human proof-of-mechanism clinical trials. After that, GSK will have an option to exclusively license worldwide rights for the products in exchange for "enhanced" financial payments to Five Prime.

Five Prime is eligible to receive as much as $30 million during the next four years, which includes an up-front payment, the purchase of Five Prime equity by GSK, research funding and option payments in connection with the research program.

Also, if GSK were to license a candidate after Five Prime has developed the candidate through the proof-of-mechanism stage, Five Prime would be eligible to receive as much as $193.5 million in option exercise fees and milestone payments, along with tiered royalties on global net sales for each product resulting from a selected drug target.

Latest News

Targacept revises previous analysis of midstage trial of investigational asthma therapy; new results suggest TC-6987 missed one of two primary endpoints Verusmed

Wednesday, April 11 2012 | Comments
Evidence Grade 0 What's This?

Targacept Inc. updated its analysis of a Phase II trial of TC-6987 as a treatment for asthma, with new data suggesting that the drug only met one of the trial's two primary endpoints.

Targacept reported last month that the drug, a modulator of the alpha7 neuronal nicotinic receptor, met the protocol-defined success criteria for both primary endpoints of the trial.

However, the company said that an error...

Tags: Asthma


AstraZeneca, Amgen to collaborate on development of five monoclonal antibodies Verusmed

Monday, April 02 2012 | Comments
Evidence Grade 0 What's This?

AstraZeneca Plc and Amgen Inc. entered into a collaboration agreement to jointly develop and commercialize five monoclonal antibodies from Amgen's clinical inflammation portfolio.

The compounds covered by the agreement include brodalumab, also known as AMG 827, which is in midstage development as a...

Tags: Asthma, Arthritis


Higher prescription cost sharing decreases drug use, increases hospitalizations among children with asthma, study shows Verusmed

Thursday, March 29 2012 | Comments
Evidence Grade 0 What's This?

Among children aged 5 years or older with asthma, greater prescription cost sharing appears to be associated with decreases in asthma medication use and higher rates of asthma-related hospitalizations, data from a new study reveal.

Researchers examined insurance claims from a benefits consulting firm for 8,834 children and adolescents aged younger than 18 years with newly diagnosed asthma who initiated asthma control therapy between 1997 and 2007. They analyzed the association...

Tags: Asthma


Targacept reports results for drug candidate in asthma, diabetes studies, will cease development in diabetes indication Verusmed

Tuesday, March 27 2012 | Comments
Evidence Grade 0 What's This?

Targacept Inc. reported top-line data from two separate exploratory midstage trials of its product candidate TC-6987, a modulator of the alpha7 neuronal nicotinic receptor.

One of the trials evaluated the drug as a treatment for type 2 diabetes, and the other evaluated it as a treatment for asthma.

The double-blind diabetes study included 112 adults, 87 of whom completed the study. Following a four-week...

Tags: Asthma




  1. No articles have been read
  1. No articles have been emailed
Videos